This trial is active, not recruiting.

Condition acute coronary syndrome
Sponsor AstraZeneca
Start date April 2015
End date May 2017
Trial size 3000 participants
Trial identifier NCT02408224, D5130R00029, NIS-CIN-BRI-2014/1


The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India. The aim of this national study is to understand the usage pattern (including the duration of treatment) of Ticagrelor in various ACS patient population undergoing PCI (Percutaneous Coronary Intervention), CABG (Coronary Artery Bypass Graft) or medical management in a real-life setting in India.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model other
Time perspective prospective
patients on Ticagrelor

Primary Outcomes

Usage pattern of Ticagrelore in real life setting
time frame: 48 Weeks
Usage pattern of Ticagrelore
time frame: 48 Weeks

Secondary Outcomes

Frequency of various risk factors
time frame: 48 Weeks

Eligibility Criteria

All participants of any age.

Inclusion Criteria: 1. Written informed consent has been provided. 2. Aged 18 years or older. 3. Male/female with ACS on Ticagrelor on discharge or ≤ 1month. 4. Patient underwent PCI, CABG or MM (Medical Management) for ACS. 5. Diagnosis of STEMI, NSTEMI or UA Exclusion Criteria: 1. Patients with medical history of intracranial hemorrhage 2. All those patients who are not fit to receive Ticagrelor as per the latest prescribing information

Additional Information

Official title A Non-interventional Prospective Observational Study to Understand the Usage Pattern of Ticagrelor in Indian Patients With Acute Coronary Syndrome.
Description This study is a multi-centre, observational, prospective study to be conducted at 60 hospitals across IndiaThe study will be initiated after obtaining written approval of Independent Ethics Committee (IEC) and written Informed consent of the patient. Patients who had been hospitalized for ACS and are on ticagrelor on discharge or on Ticagrelor therapy for ≤ 1month will be enrolled in the study and followed up for a period of 12 months. During the follow-up period of up to 12 months (according to the label), assessment visits will follow the routine clinical practice. No visits or measurements will be made mandatory by the protocol
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by AstraZeneca.